• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

byMinjee Kim
June 30, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In coronavirus disease 2019 (COVID-19) patients, molnupiravir was associated with earlier and larger reductions of C-reactive protein (CRP) as compared to placebo.

2. Participants who received molnupiravir required fewer respiratory interventions and COVID-19-related medical appointments.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Several approved monoclonal antibodies (mAB) have been shown to reduce the risk of hospitalization and severe illness in COVID-19 patients. However, many of the existing options for COVID-19 intervention require injections in-hospital or have been found to be ineffective against the Omicron (B.1.1.529) variant. Molnupiravir is an orally available mAB treatment option that has been shown to have broad-spectrum activity against SARS-CoV-2 variants of concern. Patients 18 or older with confirmed mild to moderate COVID-19 were randomly assigned to receive molnupiravir 800 mg or placebo every 12 hours for 5 days. Those in the treatment group saw an earlier and larger reduction in CRP at all study visits than placebo. Molnupiravir-treated participants also had an improvement in SpO2 values as early as three days following treatment, compared to 10 days in the placebo group. The requirement for respiratory interventions was significantly reduced for the treatment group. Finally, acute care visits for COVID-19-related symptoms were significantly lower in the treatment group than in the placebo group. A limitation is that longer-term benefits of molnupiravir therapy were not studied as the endpoint was 29 days after treatment and there could potentially be long-lasting protective effects for patients.

Click to read the study in AIM

In-Depth [randomized controlled trial]: The MOVe-OUT phase three trial examined the effect of molnupiravir on inflammatory biomarkers, respiratory intervention requirements, and medical care usage in COVID-19 patients. In total, 1,433 participants from 103 sites were randomly assigned to either receive molnupiravir (n=710) or a placebo control (n=701). Further, 152 patients in the treatment group and 151 in the placebo group received systemic corticosteroids before or during the study treatment period. Molnupiravir-treated participants had earlier and larger reductions in CRP after treatment on days three, five, 10, 15, and 29. However, these findings were not statistically significant compared to the placebo. When changes in SpO2 were examined, the treatment saw immediate improvements starting on day three, compared to day 10 for the placebo group. In the modified intention-to-treat (MITT) group, fewer patients in the treatment group required the use of respiratory interventions (Relative risk reduction [RRR] 34.3%; 95% Confidence Interval [CI], 4.3% to 54.9%). The respiratory interventions examined were conventional oxygen therapy, high-flow heated and humidified device, non-invasive mechanical ventilation, and invasive mechanical ventilation. Participants who had a COVID-19-related visit were lower in the treatment group (6.6%) compared to the placebo group (10%) (RRR 32.1%; 95% CI, 5.6% to 53.6%). 48 participants (6.8%) in the molnupiravir-treatment group and 67 participants (9.6%) in the placebo group were hospitalized during the study period. The findings suggest that molnupiravir may benefit non-hospitalized, mild to moderate COVID-19 patients by reducing health care visits/hospitalizations, and costs while alleviating symptoms.

RELATED REPORTS

BNT162b2 vaccine reduces rates of COVID-19 omicron variant infection in children

Delta variant of SARS-CoV-2 infection associated with higher changes of severe maternal morbidities

The CDC implements a community-level metrics program to inform COVID-19 policy

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: covidCOVID-19mABmild to moderate COVID-19molnupiravirmonoclonal antibodyMOVe-OUT trialSARS-CoV-2
Previous Post

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

Next Post

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

RelatedReports

Infectious Disease

BNT162b2 vaccine reduces rates of COVID-19 omicron variant infection in children

August 18, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Infectious Disease

Delta variant of SARS-CoV-2 infection associated with higher changes of severe maternal morbidities

August 17, 2022
ACP offers recommendations to improve the ACA, patient care
Chronic Disease

The CDC implements a community-level metrics program to inform COVID-19 policy

August 17, 2022
#VisualAbstract: Prasinezumab therapy does not affect Parkinson’s Disease progression
StudyGraphics

#VisualAbstract: Prasinezumab therapy does not affect Parkinson’s Disease progression

August 17, 2022
Next Post
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Newborn screening for cystic fibrosis improves nutritional outcomes
  • BNT162b2 vaccine reduces rates of COVID-19 omicron variant infection in children
  • Non-contrast CT sensitive and specific for kidney stones [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.